Abstract
Objectives
Current protocols for processing multiple prostate biopsy cores per case are uneconomical and cumbersome. Tissue fragmentation and loss compromise cancer diagnosis. We sought to study an alternate method to improve the processing and diagnosis of prostate cancer.
Methods
Two sets of sextant biopsy specimens from near-identical locations were obtained ex vivo from 48 prostate specimens. One set was processed in the standard fashion, while the other was processed using the BxChip, a proprietary biomimetic matrix that accommodates six cores on a single chip. Parameters including grossing, embedding, sectioning and reading time, tissue length, and fragmentation degree were compared.
Results
A significant reduction (more than threefold) in preanalytical and analytical time was observed using the multiplex method. Nonlinear fragmentation was absent, in contrast to standard processing.
Conclusions
The BxChip reduced tissue fragmentation and increased the efficiency of prostate biopsy diagnosis. It also resulted in overall cost savings and significantly increased tissue length.
American Journal of Clinical Pathology, Volume 152, Issue 6, December 2019, Pages 757–765, https://doi.org/10.1093/ajcp/aqz101
Related posts:
- The Lumea BxChip® Saves Labs Time, Money, and Improves Quality
- Lumea BxChip® Increased Both Tissue Yield and Prostate Cancer Detection
- MP16-19 BxChip™ Clinical Tissue Array Increases Cancer Detection Rate & Amount Of Tissue Available For Pathologist Review
- Quality Assurance and Cost Reduction in Histopathology Laboratories Using Tissue Microarrays
